---
title: "Ubrelvy (ubrogepant) in acute treatment of migraine: Safety questions"
description: "Safety questions on Ubrelvy (ubrogepant) in acute treatment of migraine, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Safety evidence, Side effects, and Warnings. Questions: Does Ubrelvy prolong the QT interval? What side effects occurred when Ubrelvy was taken during the prodrome? What are the most common side effects of Ubrelvy? Does Ubrelvy cause drowsiness or fatigue? 5 further questions follow. 9 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/ubrelvy--acute-treatment-of-migraine/safety"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Ubrelvy (ubrogepant) in acute treatment of migraine: Safety questions

Manufacturer: AbbVie Inc.  
Prescribing information: [Ubrelvy](https://www.rxabbvie.com/pdf/ubrelvy_pi.pdf)

## Safety evidence

<a id="ubrelvy-qt-interval"></a>

### Does Ubrelvy prolong the QT interval?

> “At a dose 2 times the maximum recommended daily dose, UBRELVY does not prolong the QT 
> interval to any clinically relevant extent.”

Source: [UBRELVY: Prescribing information, page 9, captured 2026-11-14](https://www.rxabbvie.com/pdf/ubrelvy_pi.pdf#page=9)

## Side effects

<a id="ubrelvy-prodrome-side-effects"></a>

### What side effects occurred when Ubrelvy was taken during the prodrome?

> “Safety in the prodrome trial was consistent with pivotal clinical trials<sup>1,3</sup>
> The most common TEAEs (≥2% in either group) were nausea (UBRELVY 100 mg: 5% vs placebo: 3%), dizziness (2% vs 3%), fatigue (3% vs 2%), and somnolence (2% vs 1%).<sup>#</sup>”

Source: [UBRELVY: UBRELVY® Results & Efficacy Data, captured 2026-11-14](https://www.ubrelvyhcp.com/results#:~:text=Safety%20in%20the%20prodrome%20trial,2%25%29%2C%20and%20somnolence%20%282%25%20vs)

> “TEAEs reflected any adverse events reported within 48 hours after taking UBRELVY or placebo.<sup>3</sup>”

Source: [UBRELVY: UBRELVY® Results & Efficacy Data, captured 2026-11-14](https://www.ubrelvyhcp.com/results#:~:text=TEAEs%20reflected%20any%20adverse%20events,hours%20after%20taking%20UBRELVY%20or)

Note: After nausea, each pair of percentages is UBRELVY 100 mg followed by placebo. The Ubrelvy Prescribing Information does not describe this study.

<a id="ubrelvy-side-effects"></a>

### What are the most common side effects of Ubrelvy?

> “The safety of UBRELVY was evaluated in 3,624 subjects who received at least one dose of 
> UBRELVY. In two randomized, double-blind, placebo-controlled, Phase 3 trials in adult patients 
> with migraine (Studies 1 and 2), a total of 1,439 patients received UBRELVY 50 mg or 100 mg 
> [see Clinical Studies (14)]. Of the UBRELVY-treated patients in these 2 studies, approximately 
> 89% were female, 82% were White, 15% were Black, and 17% were of Hispanic or Latino 
> ethnicity. The mean age at study entry was 41 years (range of 18-75 years).”

Source: [UBRELVY: Prescribing information, page 4, captured 2026-11-14](https://www.rxabbvie.com/pdf/ubrelvy_pi.pdf#page=4)

> “Table 2: Adverse Reactions Occurring in At Least 2% and at a Frequency 
> Greater than Placebo in Studies 1 and 2 
>
> Placebo 
>
> (N= 984) 
> % 
> UBRELVY  
> 50 mg 
> (N=954) 
> % 
> UBRELVY  
> 100 mg 
> (N=485) 
> % 
> Nausea 
> 2 
> 2 
> 4 
> Somnolence* 
> 1 
> 2 
> 3 
> Dry Mouth 
> 1 
> <1 
> 2 
> *Somnolence includes the adverse reaction-related terms sedation and fatigue.”

Source: [UBRELVY: Prescribing information, page 4, captured 2026-11-14](https://www.rxabbvie.com/pdf/ubrelvy_pi.pdf#page=4)

Note: Table 2 columns are placebo (N=984), UBRELVY 50 mg (N=954), and UBRELVY 100 mg (N=485), in that order (% of patients).

<a id="ubrelvy-drowsiness"></a>

### Does Ubrelvy cause drowsiness or fatigue?

> “Somnolence* 
> 1 
> 2 
> 3”

Source: [UBRELVY: Prescribing information, page 4, captured 2026-11-14](https://www.rxabbvie.com/pdf/ubrelvy_pi.pdf#page=4)

> “*Somnolence includes the adverse reaction-related terms sedation and fatigue.”

Source: [UBRELVY: Prescribing information, page 4, captured 2026-11-14](https://www.rxabbvie.com/pdf/ubrelvy_pi.pdf#page=4)

> “The most common side effects of UBRELVY are nausea and sleepiness.”

Source: [UBRELVY: Prescribing information, page 17, captured 2026-11-14](https://www.rxabbvie.com/pdf/ubrelvy_pi.pdf#page=17)

Note: The Somnolence row of Table 2 gives placebo, UBRELVY 50 mg, and UBRELVY 100 mg, in that order (% of patients in Studies 1 and 2). The last passage is from the Patient Information printed with the Prescribing Information.

<a id="ubrelvy-long-term-side-effects"></a>

### What are the long-term side effects of Ubrelvy?

> “Long-term safety was assessed in 813 patients, dosing intermittently for up to 1 year in an open-
> label extension study. Patients were permitted to treat up to 8 migraines per month with 
> UBRELVY. Of these 813 patients, 421 patients were exposed to 50 mg or 100 mg for at least 6 
> months, and 364 patients were exposed to these doses for at least one year, all of whom treated at 
> least two migraine attacks per month, on average. In that study, 2.5% of patients were withdrawn 
> from UBRELVY because of an adverse reaction. The most common adverse reaction resulting in 
> discontinuation in the long-term safety study was nausea.”

Source: [UBRELVY: Prescribing information, page 4, captured 2026-11-14](https://www.rxabbvie.com/pdf/ubrelvy_pi.pdf#page=4)

## Warnings

<a id="ubrelvy-contraindications"></a>

### Who should not take Ubrelvy (contraindications)?

> “UBRELVY is contraindicated: 
> • 
> With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions (7.1)] 
> • 
> In patients with a history of serious hypersensitivity to ubrogepant or any component of 
> UBRELVY. Reactions have included anaphylaxis, dyspnea, and facial or throat edema 
> [see Warnings and Precautions (5.1)]”

Source: [UBRELVY: Prescribing information, page 3, captured 2026-11-14](https://www.rxabbvie.com/pdf/ubrelvy_pi.pdf#page=3)

<a id="ubrelvy-allergic-reactions"></a>

### Can Ubrelvy cause allergic reactions?

> “Hypersensitivity reactions, including anaphylaxis, dyspnea, facial or throat edema, rash, 
> urticaria, and pruritus, have been reported with use of UBRELVY. Hypersensitivity reactions 
> can occur minutes, hours, or days after administration. Most reactions occurred within hours 
> after dosing and were not serious, and some reactions led to discontinuation. If a serious or 
> severe hypersensitivity reaction occurs, discontinue UBRELVY and institute appropriate therapy 
> [see Contraindications (4) and Adverse Reactions (6.2)].”

Source: [UBRELVY: Prescribing information, page 3, captured 2026-11-14](https://www.rxabbvie.com/pdf/ubrelvy_pi.pdf#page=3)

<a id="ubrelvy-high-blood-pressure"></a>

### Can Ubrelvy raise blood pressure?

> “Development of hypertension and worsening of pre-existing hypertension have been reported 
> following the use of CGRP antagonists, including UBRELVY, in the postmarketing setting. 
> Some of the patients who developed new-onset hypertension had risk factors for hypertension. 
> There were cases requiring initiation of pharmacological treatment for hypertension and, in some 
> cases, hospitalization. Hypertension may occur at any time during treatment, but was most 
> frequently reported within 7 days of therapy initiation. The CGRP antagonist was discontinued in 
> many of the reported cases. 
> Monitor patients treated with UBRELVY for new-onset hypertension, or worsening of 
> pre-existing hypertension, and consider whether discontinuation of UBRELVY is warranted if 
> evaluation fails to establish an alternative etiology or blood pressure is inadequately controlled.”

Source: [UBRELVY: Prescribing information, page 3, captured 2026-11-14](https://www.rxabbvie.com/pdf/ubrelvy_pi.pdf#page=3)

> “Because these reactions are reported voluntarily from a population of uncertain size, it is not 
> always possible to reliably estimate their frequency or establish a causal relationship to drug 
> exposure.”

Source: [UBRELVY: Prescribing information, page 5, captured 2026-11-14](https://www.rxabbvie.com/pdf/ubrelvy_pi.pdf#page=5)

Note: The label describes postmarketing reports for the CGRP antagonist class, including Ubrelvy; the last passage is from the Postmarketing Experience section of the label.

<a id="ubrelvy-raynauds"></a>

### Can Ubrelvy cause Raynaud's phenomenon?

> “Development of Raynaud’s phenomenon and recurrence or worsening of pre-existing Raynaud’s 
> phenomenon have been reported in the postmarketing setting following the use of CGRP 
> antagonists, including UBRELVY. In reported cases with small molecule CGRP antagonists, 
> symptom onset occurred a median of 1.5 days following dosing. Many of the cases reported 
> serious outcomes, including hospitalizations and disability, generally related to debilitating pain. 
> In most reported cases, discontinuation of the CGRP antagonist resulted in resolution of 
> symptoms.”

Source: [UBRELVY: Prescribing information, page 3, captured 2026-11-14](https://www.rxabbvie.com/pdf/ubrelvy_pi.pdf#page=3)

> “UBRELVY should be discontinued if signs or symptoms of Raynaud’s phenomenon develop, 
> and patients should be evaluated by a healthcare provider if symptoms do not resolve. Patients 
> with a history of Raynaud’s phenomenon should be monitored for, and informed about the 
> possibility of, worsening or recurrence of signs and symptoms.”

Source: [UBRELVY: Prescribing information, page 4, captured 2026-11-14](https://www.rxabbvie.com/pdf/ubrelvy_pi.pdf#page=4)

> “Because these reactions are reported voluntarily from a population of uncertain size, it is not 
> always possible to reliably estimate their frequency or establish a causal relationship to drug 
> exposure.”

Source: [UBRELVY: Prescribing information, page 5, captured 2026-11-14](https://www.rxabbvie.com/pdf/ubrelvy_pi.pdf#page=5)

Note: The label describes postmarketing reports for the CGRP antagonist class, including Ubrelvy; the symptom-onset figure is from reported cases with small molecule CGRP antagonists. The last passage is from the Postmarketing Experience section of the label.

## Related pages
- [Medical information: Ubrelvy (ubrogepant): Acute treatment of migraine](https://www.evicenter.com/medical-information/ubrelvy--acute-treatment-of-migraine)
- [Indication](https://www.evicenter.com/medical-information/ubrelvy--acute-treatment-of-migraine/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/ubrelvy--acute-treatment-of-migraine/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/ubrelvy--acute-treatment-of-migraine/clinical-trials)
- [Specific populations](https://www.evicenter.com/medical-information/ubrelvy--acute-treatment-of-migraine/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/ubrelvy--acute-treatment-of-migraine/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/ubrelvy--acute-treatment-of-migraine/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/ubrelvy--acute-treatment-of-migraine/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/ubrelvy--acute-treatment-of-migraine/access-and-coverage)
